SCHEMBL31577611

SCHEMBL31577611

Clc1ccc2nc3c(cc2c1)CCN3c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.60
ALDH1A1 P00352 7/20 0.60
MEN1 O00255 6/20 0.60
KMT2A Q03164 6/20 0.60
GAA P10253 4/20 0.60
MAPK1 P28482 2/20 0.60
UBE2N P61088 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
HPGD P15428 5/20 0.48
LMNA P02545 3/20 0.48
NPC1 O15118 2/20 0.45
RXFP1 Q9HBX9 1/20 0.45
MAPT P10636 6/20 0.44
TSHR P16473 3/20 0.44
HSD17B10 Q99714 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
POLB P06746 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9851365 0.77 KDM4E (0.72) KDM4EALDH1A1MEN1KMT2AGAA
SCHEMBL4640583 0.72 HRH4 (0.43) KDM4EALDH1A1MEN1KMT2AGAA
SCHEMBL14294210 0.71 SRD5A1 (0.51) ALDH1A1HPGDMAPTPOLBCYP11B1
SCHEMBL7976237 0.68 SMN1; SMN2 (0.38) KDM4EMEN1KMT2AGAAL3MBTL1
SCHEMBL29120935 0.66 KDM4E (0.47) KDM4EALDH1A1MEN1KMT2AGAA
SCHEMBL30633048 0.66 KDM4E (0.47) KDM4EALDH1A1MEN1KMT2AGAA
SCHEMBL7966498 0.65 HRH4 (0.40) MEN1KMT2ANPC1MAPTSMN1; SMN2
SCHEMBL10140203 0.65 MAT2A (0.44) MEN1KMT2ANPC1SMN1; SMN2RAB9A
SCHEMBL28549714 0.65 ESR2 (0.66) KDM4EMEN1KMT2ALMNANPC1
SCHEMBL5045994 0.65 KDM4E (0.88) KDM4EALDH1A1MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163056-A1 NONMUSCLE MYOSIN II INHIBITORS THE UNIV OF FLORIDA RESEARCH FOUNDATION INC (US) 2025-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163056-A1 NONMUSCLE MYOSIN II INHIBITORS MYH2, MYO3B, MYO1B KDM4E 3550/4885ALDH1A1 2712/4885MEN1 1652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.